NeuroBo Pharmaceuticals, Inc. announced that DA-1726, a novel oxyntomodulin analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, had been shown to elicit superior weight loss efficacy compared to Semaglutide (SEMA) and Tirzepatide (TIR) in preclinical testing. This, and other data, was presented in one ePoster theater discussion and two general poster presentations at the American Diabetes Association's 83rd Scientific Sessions, held June 23-26, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.9 USD | -0.76% | -2.01% | +5.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.50% | 1.93Cr | |
+18.77% | 12TCr | |
+14.05% | 11TCr | |
-7.16% | 2.42TCr | |
+2.07% | 2.28TCr | |
-10.79% | 1.8TCr | |
-41.74% | 1.64TCr | |
-13.47% | 1.64TCr | |
+2.23% | 1.36TCr | |
+27.13% | 1.17TCr |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- Neurobo Pharmaceuticals, Inc. Announces Da-1726 Effectively Reduces Body Weight and Glycemic Control Data At the American Diabetes Association's 83Rd Scientific Sessions